Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects
Authors:
Open Access
- 27 June 2019
- journal article
- letter
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 10 (10) , 764-769
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemiaNature Medicine, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2015
- Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15Blood, 2014
- Chimeric Antigen Receptor Therapy for CancerAnnual Review of Medicine, 2014
- IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursorsBlood, 2013
- Treating cancer with genetically engineered T cellsTrends in Biotechnology, 2011
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.Proceedings of the National Academy of Sciences, 1993
- Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regionsBiochemical and Biophysical Research Communications, 1987